Evolus Inc (NASDAQ: EOLS) is a medical aesthetics company that commercializes botulinum toxin products for aesthetic procedures. Revenue comes from product sales of Jeuveau, a prescription neurotoxin used by aesthetic practitioners, and Evolysse, a hyaluronic acid filler, sold directly to customers such as plastic surgeons, dermatologists, and medical spas. Evolus operates a direct sales model supported by digital technology and a consumer loyalty program that allocates a portion of invoice price to deferred revenue redeemable by participating customers. The company is headquartered in Newport Beach, California, at 520 Newport Center Drive, in approximately 30,716 square feet of leased space. As of December 31, 2025, Evolus carried $150.0 million in principal debt, none due in 2026, under variable-rate Pharmakon Term Loans with approximately $59.4 million in future interest payments. The company pays royalties to Medytox under settlement agreements that reduce profitability for the duration of those obligations. Jeuveau is manufactured by Daewoong, and supply continuity depends on the terms of the Medytox settlement remaining in force.

Revenue model

Transactional product sales of Jeuveau and Evolysse to aesthetic practitioners, with a consumer loyalty program that defers a portion of invoice revenue until customers redeem rewards for future product at no additional cost.

Products and services

Jeuveau (prabotulinumtoxinA), a prescription botulinum toxin type A for aesthetic use; Evolysse, a hyaluronic acid dermal filler; digital technology platform supporting sales and customer engagement; consumer loyalty rewards program.

Customers and end markets

Aesthetic practitioners including plastic surgeons, dermatologists, and medical spas. End market is elective aesthetic procedures, which are sensitive to consumer discretionary spending. Tariffs enacted by the United States as of the filing date have been cited as negatively affecting consumer sentiment and aesthetic procedure demand.

Value-chain role

Downstream commercialization and direct sales of botulinum toxin and filler products manufactured by third-party supplier Daewoong. Evolus does not manufacture; it licenses, imports, markets, and sells finished aesthetic injectables to practitioners.

Geographic exposure

United States primary market. Regulatory exposure noted in the United Kingdom and European Union in the 10-K filing dated 2026-03-03, indicating some international commercial or regulatory activity.

Source: SEC 10-K, filed 2026-03-03

Industry: Pharmaceutical Preparations Peers: Atea Pharmaceuticals Inc Tvardi Therapeutics Inc Edgewise Therapeutics Inc Esperion Therapeutics Inc Ocular Therapeutix Inc Johnson & Johnson Nuvation Bio Inc Rani Therapeutics Holdings Inc Tarsus Pharmaceuticals Inc Tricida, Inc.